Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, impaired insulin sensitivity, and chronic low-grade inflammation. However, the pathogenic mechanism of NAFLD is poorly understood, which hinders the exploration of possible treatments. Here, we report that ubiquitin-specific protease 18 (USP18), a member of the deubiquitinating enzyme family, plays regulatory roles in NAFLD progression. Expression of USP18 was down-regulated in the livers of nonalcoholic steatohepatitis patients and high-fat diet (HFD)-induced or genetically obese mice. When challenged with HFD, hepatocyte-specific USP18 transgenic mice exhibited improved lipid metabolism and insulin sensitivity, whereas mice knocked out of USP18 expression showed adverse trends regarding hepatic steatosis and glucose metabolic disorders. Furthermore, the concomitant inflammatory response was suppressed in USP18-hepatocyte-specific transgenic mice and promoted in USP18-hepatocyte-specific knockout mice treated with HFD. Mechanistically, hepatocyte USP18 ameliorates hepatic steatosis by interacting with and deubiquitinating transforming growth factorb-activated kinase 1 (TAK1), which inhibits TAK1 activation and subsequently suppresses the downstream c-Jun N-terminal kinase and nuclear factor kappa B signaling pathways. This is further validated by alleviated steatotic phenotypes and highly activated insulin signaling in HFD-fed USP18-hepatocyte-specific knockout mice administered a TAK1 inhibitor. The therapeutic effect of USP18 on NAFLD relies on its deubiquitinating activity because HFD-fed mice injected with active-site mutant USP18 failed to inhibit hepatic steatosis. Conclusion: USP18 associates with and deubiquitinates TAK1 to protect against hepatic steatosis, insulin resistance, and the inflammatory response. (HEPATOLOGY 2017;66:1866-1884.
N onalcoholic fatty liver disease (NAFLD) has become a worldwide health concern as its prevalence has increased because of lifestyle changes. NAFLD is caused by ectopic fat accumulation in the liver, mainly due to excessive fat uptake from foods, enhanced hepatic de novo lipid synthesis, and reduced fatty acid b-oxidation.
(1-4) Insulin resistance and inflammation have key roles in the pathogenesis of NAFLD, inducing a vicious circle among hyperinsulinemia, lipid metabolic disturbance, and chronic inflammation. (4, 5) Various signaling pathways are related to the steatotic process in the liver, such as Abbreviations: Ad, adenoviral; BODIPY, boron-dipyrromethene; DMSO, dimethyl sulfoxide; DUB, deubiquitinating; GFP, green fluorescent protein; GTT, glucose tolerance test; HA, hemagglutinin; H&E, hematoxylin and eosin; HFD, high-fat diet; HKO, hepatocyte-specific knockout; HTG, hepatocyte-specific transgenic; IKKb, IjB kinase b; IL, interleukin; IRS1, insulin receptor substrate 1; ITT, insulin tolerance test; JNK, c-Jun Nterminal kinase 1; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NC, normal chow; NEFA, nonesterified fatty acid; NF-jB, nuclear factor kappa B; NTG, nontransgenic; PA, palmitate; PAS, periodic acid-Schiff; pcDNA, plasmid cytomegalovirus promoter DNA; SD, standard deviation; sh, short hairpin; TAK1, transforming growth factor-b-activated kinase 1; TC, total cholesterol; TG, triglyceride; USP18, ubiquitin-specific protease 18; 5Z-7-OX, 5Z-7-oxozeaenol.
insulin-signaling cascades and mitogen-activated protein kinase and nuclear factor kappa B (NF-jB) signaling pathways. (6) (7) (8) (9) However, the molecular mechanisms that are involved in this pathogenic process remain poorly understood and require further investigation.
Ubiquitin-specific protease 18 (USP18), which is also known as UBP43, (10) is a member of the deubiquitinating (DUB) enzymes and is endowed with various functions, including apoptotic suppression, (11) neoplastic regulation, (12) (13) (14) (15) and innate immunity modulation. (16) (17) (18) (19) Previous studies mainly focused on the regulatory function of USP18 on the antiviral and antibacterial infection responses by inhibiting type I interferon signaling. (16) (17) (18) (19) There is also evidence indicating that USP18 knockout resulted in enhanced interferon signaling and thus exerted antineoplastic effects in breast cancers (13) and hematologic tumors. (14) Considering the tight relationship between inflammation and metabolic disorders, (20, 21) USP18 might also participate in the development of hepatic steatosis. Interestingly, we observed that expression of USP18 was down-regulated in the livers of nonalcoholic steatohepatitis (NASH) patients and high-fat diet-induced (HFD) or genetic deficiency-induced obese mice. However, the potential effects of USP18 on NAFLD have not been investigated yet.
In this study, we used hepatocyte-specific USP18 transgenic (USP18-HTG) and knockout (USP18-HKO) mice with HFD administration to explore the role of USP18 in NAFLD and proved that USP18 protects against hepatic steatosis, insulin resistance, and inflammation. More importantly, we elucidated the pathogenic mechanism: USP18 deubiquitinates transforming growth factor-b-activated kinase 1 (TAK1) and thus inhibits its activation to influence the downstream c-Jun N-terminal kinase (JNK) and NF-jB signaling pathways, providing a novel target for NAFLD treatments.
Materials and Methods

MICE AND DIETS
To create the USP18-HTG mice, we microinjected a reconstruct containing the USP18 coding sequence after the CAG-loxp-CAT-loxp cassette into C57BL/ 6J embryos and crossed these mice with albumin-Cre mice (Jackson Laboratory, Bar Harbor, ME; Supporting Fig. S1A ). The USP18-HKO mice were generated by mating USP18 flox/flox mice with albumin-Cre mice (Supporting Fig. S1B ). The leptin-deficient (ob/ob) mice used in this study were purchased from Jackson Laboratory. To achieve USP18 overexpression in the livers of ob/ob mice, we injected reconstructed adenovirus (5 3 10 9 pfu; once a week for 4 weeks) through the jugular vein of 8-week-old ob/ob mice (ob/ob-Ad-USP18) fed normal chow (NC). The ob/ob mice injected with Ad green fluorescent protein (GFP) served as controls. 5Z-7-Oxozeaenol (5Z-7-OX; O9890-1 MG; Sigma, St. Louis, MO) was administered intraperitoneally (5 mg/kg, once a week for 4 weeks) into USP18-Flox and USP18-HKO mice after 8-week HFD feeding to specifically inhibit TAK1 activation. The AdUSP18-M was an adenovirus encoding active-site mutant USP18 with a replacement of its active-site Cys 64 by Ser. AdUSP18 or AdUSP18-M was injected into HFD-fed C57 mice to achieve USP18 or USP18-M overexpression in the liver. HFD mice injected with AdGFP were used as controls.
All mice (aged 8-10 weeks) were nurtured under controlled conditions (temperature 23 6 28C, 12-hour/12-hour light/dark cycle). NAFLD model mice and control mice were continuously fed an HFD (protein, 20%; fat, 60%; carbohydrates, 20%; D-12492;
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Research Diets, NJ) or NC (protein, 20%; fat, 10%; carbohydrates, 70%; D-12450B; Research Diets) for 12 weeks, respectively. Body weight and fasting blood glucose and insulin levels were measured every 2 weeks. Eight-week-old ob/ob mice were fed NC for 4 weeks with corresponding treatments. All animal experiments were approved by the Animal Care and Use Committee of Renmin Hospital at Wuhan University, and humane care was provided according to the criteria stated in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health.
HUMAN LIVER SAMPLES
Human liver samples were provided by the Renmin Hospital at Wuhan University. Hepatic steatotic specimens were collected from patients with NASH who had undergone liver transplantation or biopsy, and nonsteatotic livers were obtained from individuals diagnosed with liver hemangioma and hepatic cyst and accepted liver surgeries. (22) The clinical information and histological features of NASH patients are listed in Supporting Table S2 . All procedures involving human samples followed the principles in the Declaration of Helsinki and were approved by the review board of Renmin Hospital at Wuhan University. Written informed consent was obtained from the subjects or families of liver donors.
METABOLIC STUDIES
Fasting blood glucose and insulin levels were tested by glucometer (Life Scan, Milpitas, CA) and enzymelinked immunosorbent assay (Millipore, Billerica, MA). For the glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs), an intraperitoneal injection of 1 g/kg glucose or 0.75 U/kg insulin was given to HFD mice, respectively; blood collection was conducted at 15, 30, 60, and 120 minutes. Hepatic triglyceride (TG), total cholesterol (TC), and nonesterified fatty acid (NEFA) levels were all measured by commercial kits (Wako, Osaka, Japan).
EVALUATION OF LIVER FUNCTION AND SYSTEMIC INFLAMMATION
The concentrations of the hepatic enzymes alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were analyzed using a spectrophotometer (Chemix 180i; Sysmex Shanghai Ltd., Shanghai, China) according to the manufacturer's instructions. Levels of the serum inflammatory indicators were measured by enzyme-linked immunosorbent assay.
HISTOLOGICAL ANALYSIS AND IMMUNOFLUORESCENCE
Frozen liver sections were stained with oil red O (Sigma-Aldrich, St. Louis, MO), and those embedded in paraffin were stained with hematoxylin and eosin (H&E). Periodic acid-Schiff (PAS) staining was employed to manifest glycogen in hepatocytes. Expression and localization of USP18 were detected by immunofluorescence.
PRIMARY HEPATOCYTE ISOLATION, CULTIVATION, AND TREATMENT
Primary hepatocytes were isolated from mice 6-8 weeks old following the steps reported previously. (23) Hepatocytes were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin-streptomycin in a 5% CO 2 /watersaturated incubator at 378C. Palmitate (PA) was added to a portion of the cultured cells, and this portion was incubated for an additional 24 hours to generate a steatotic cell model before recombinant adenoviral infection.
BORON-DIPYRROMETHENE-C16 FLUORESCENCE STAINING
The boron-dipyrromethene (BODIPY)-C16 fluorescence assay was performed to evaluate the fatty acid uptake in L02 cells challenged with AdUSP18 or Adshort hairpin (sh)-USP18. Cells treated with GFP or RNA vectors served as controls. After being starved for 3 hours, the cells were incubated with 100 nM BODIPY-C16 for 5 minutes in phosphate-buffered saline. After washing with phosphate-buffered saline, the cells were fixed with paraformaldehyde (pH 7.4) for 10 minutes. DP2-BSW software (version 2.2) was used to capture fluorescence microscopic images.
TOTAL GLYCOGEN ANALYSIS
Liver tissue (100 mg) was measured for each group and homogenized in 300 mL of isopropyl alcohol, followed by centrifugation. The supernatants were used to detect total glycogen content according to the instructions of the Glycogen Assay Kit (BioVision). The amount of glycogen was normalized to the amount of protein.
RNA EXTRACTION AND QUANTITATIVE REAL-TIME PCR
Total RNA was extracted from liver specimens or cultured hepatocytes, followed by complementary DNA synthesis. Quantitative real-time PCR was performed with the SYBR Green PCR Master Mix (04887352001; Roche). The targeted gene transcription levels were calculated by normalizing to b-actin expression.
WESTERN BLOTTING
After extraction from mouse or human liver samples or cultured cells, each protein sample (50 mg) was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (Millipore). Then the corresponding primary and secondary antibodies were incubated to visualize the protein. All antibodies used in this study are listed in Supporting Table S4 .
PLASMID CONSTRUCTS
psi-sp6-Flag-USP18, plasmid cytomegalovirus promoter DNA 5 (pcDNA5)-hemagglutinin (HA)-USP18, and pcDNA5-Flag-USP18 were generated by cloning the coding region of human USP18 into psisp6-Flag-C1, pcDNA5-HA-C1, and pcDNA5-Flag-C1, respectively. pcDNA5-HA-TAK1 was created by cloning the human TAK1 gene into pcDNA5-HA-C1. The truncated USP18 fragments (1-54, 55-372, 155-372, and 255-372 amino acids) and TAK1 fragments (1-480, 1-390, 391-579, 1-300, and 301-579 amino acids) were obtained by PCR and cloned into pcDNA5-Flag-C1. Site-directed mutagenesis was performed by PCR. All plasmids were verified by sequencing. Primers used for plasmid constructs are listed in Supporting Table S5 .
IMMUNOPRECIPITATION
After cotransfection with the reconstructs, 293T cells were lysed and the lysates precleared and incubated with the indicated primary antibodies and Protein G-agarose (11243233001; Roche). Immunoprecipitated proteins were analyzed by immunoblotting with the indicated primary antibodies. The corresponding secondary antibodies were conjugated to horseradish peroxidase.
IN VIVO UBIQUITINATION ASSAYS
The cells were lysed with 1% sodium dodecyl sulfate lysis buffer and denatured by heating. Lysates were diluted 10-fold with regular lysis buffer containing Protease Inhibitor Cocktail Tablets (Roche, Indianapolis, IN). After centrifugation, the supernatants were subjected to immunoprecipitation and western blot analysis with specific antibodies.
STATISTICAL ANALYSIS
All data in this study are presented as the mean 6 standard deviation (SD), calculated using SPSS software (version 21.0). Statistical differences were analyzed by the Student two-tailed t test (for comparisons between two groups) or one-way analysis of variance (for comparisons between four groups), followed by Fisher's least significant difference (assuming equal variances) or Tamhane's T2 post hoc test (assuming unequal variances). P < 0.05 was considered statistically significant.
ADDITIONAL METHODS
Detailed methods are provided in Supporting Information.
Results
REDUCED EXPRESSION OF USP18 WAS DETECTED IN THE LIVERS OF NASH PATIENTS AND OBESE MICE
We analyzed liver specimens from subjects without steatosis and NASH patients by western blot and found that expression of USP18 was reduced in those from NASH patients (Fig. 1A) . Although higher expression of USP18 was detected in the livers of HFD-induced mice at early stages, USP18 expression decreased substantially after 4 weeks of HFD feeding (Fig. 1B) . A similar phenomenon was observed in ob/ ob mice (Fig. 1C) . The immunofluorescence assay manifested a dramatically reduced USP18 expression in the livers of HFD mice, particularly in the cytoplasm of the hepatocytes (Fig. 1D ). These phenomena led us to explore how USP18 was down-regulated in S2A ). Also, no significant differences in USP18 mRNA expression were found between NC-fed and HFD-fed mice or 2-week-old and 8-week-old ob/ob mice (Supporting Fig. S2B,C) . Therefore, we considered that the HFD-induced decrease of USP18 was due to protein degradation, which mainly occurred in proteasomes and lysosomes. (24) In PA-treated L02 cells, USP18 expression decreased as the PA concentration increased, and this PA-induced reduction of USP18 could be blocked by proteasome inhibitor (MG132) but not lysosome inhibitor (chloroquine) (Fig. 1E) . Figure 1F shows that the K48-linked polyubiquitination of USP18 was increased in PA-treated L02 cells, implying that the proteolysis of USP18 was through the ubiquitin-proteasome pathway.
USP18 OVEREXPRESSION AMELIORATES HEPATIC STEATOSIS
Lipid metabolic imbalance in the liver is a defining characteristic of NAFLD. To explore the effects of USP18 on hepatic lipid metabolism, we generated USP18-HTG mice and used the nontransgenic (NTG) littermates as controls (Supporting Fig. S3A ). Mice were fed NC or HFD for 12 weeks. Figure 2A shows that the liver weights of the USP18-HTG HFD mice were much lower than those of the NTG controls, despite negligible changes in their body weights. TG, TC, and NEFA contained in the liver were significantly reduced in HFD-fed mice overexpressing USP18 (Fig.  2B ). In agreement with the changes in the hepatic lipid contents, fewer lipid droplets were found in the livers of USP18-HTG mice challenged with HFD, as visualized by H&E and oil red O staining (Fig. 2C) . Additionally, we observed reduced fatty acid uptake in the PAinduced L02 cells with adenovirus-mediated up-regulation of USP18 expression (AdUSP18) through the BODIPY-C16 fluorescence assay (Fig. 2D) (Fig.  2E) . What is more, the lipid levels (TG and TC) and low-density lipoprotein concentrations in the sera of USP18-HTG mice subjected to HFD challenge were reduced, whereas the high-density lipoprotein level was increased (Fig. 2F) . Additionally, the USP18-HTG mice exhibited better liver functions, as indicated by the serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase concentrations (Fig.  2G) , further validating the protective effects of USP18 against hepatic steatosis.
USP18 OVEREXPRESSION ATTENUATES INSULIN RESISTANCE AND INFLAMMATION
Insulin resistance and inflammation are vital parts in the development of hepatic steatosis. (25, 26) USP18- HTG mice exhibited decreased fasting blood glucose and insulin levels in contrast with their control littermates fed HFD (Fig. 3A,B) . Reductions in blood glucose level relative to that of the controls were also detected in HFD-treated USP18-HTG mice through an intraperitoneal GTT (Fig. 3C) and ITT (Fig. 3D) . Moreover, the USP18-HTG mice stored more glycogen in their livers after HFD administration, as observed by PAS staining (Fig. 3E) and validated by the hepatocyte glycogen content analysis (Fig. 3F) . Relevant to the glycogen alterations, the mRNA expression levels of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase catalytic subunit (G6PC), two key enzymes regulating gluconeogenesis, were reduced in the livers of USP18-HTG mice compared to the NTG controls (Fig. 3G ). In addition, we analyzed the phosphorylation of crucial participants in insulin-signaling cascades. (2) Figure 3H shows that the expression of Tyr608-phosphorylated insulin receptor substrate 1 (IRS1) and that of Ser473-phosphorylated Akt were up-regulated, whereas Ser307-phosphorylated IRS1 expression was reduced, in the livers of USP18-HTG HFD mice. Phosphorylated IRS1
Ser307 is related to the uncoupling of IRS1 from the insulin receptor, (27) and this reductive phenomenon, combined with the increased IRS Tyr608 and Akt Ser473 phosphorylation, revealed enhanced efficacy of insulin signal transduction in the livers of USP18-HTG HFD mice. Inflammation is a hallmark of HFD-induced NAFLD, and we detected several proinflammatory indicators, including tumor necrosis factor-a, interleukin-1b (IL-1b), IL-2, IL-4, IL-6, and monocyte chemoattractant protein-1, in the sera of USP18-HTG mice fed HFD. (21) These inflammation factors were reduced in USP18-HTG HFD mice (Fig. 3I) , and the mRNA levels of IL-6, tumor necrosis factor-a, monocyte chemoattractant protein-1, and inducible nitric oxide synthase were also decreased by USP18 overexpression (Fig. 3J) . Because the JNK and NF-jB pathways are vital players in insulin-signaling cascades and inflammation, (28) (29) (30) we examined these pathways by western blot. The phosphorylation of JNK1 (not JNK2) and IjB kinase b (IKKb) was inhibited in the livers of USP18-HTG HFD mice, whereas the expression of IjBa, the inhibitory element in the NF-jB pathway, was up-regulated (Fig. 3K) . These alterations led to a highly activated insulin-signaling pathway and attenuated inflammation. (29, 31) 
USP18 DEFICIENCY AGGRAVATES HEPATIC STEATOSIS, INSULIN RESISTANCE, AND INFLAMMATION
To further verify the steatotic regulatory function of USP18, we created USP18-HKO mice and subjected them to NC or HFD for 12 weeks. USP18 flox/flox (USP18-Flox) mice served as controls (Supporting Fig. S3B ). The USP18-HKO mice gained more liver weight than the USP18-Flox mice, although their body weights were similar (Fig. 4A ). HFD mice with depleted USP18 expression in hepatocytes displayed adverse trends in terms of hepatic lipid contents (TG, TC, NEFA) and lipid droplet accumulation relative to the Flox ones (Fig. 4B,C) . Under PA stimulation, fatty acid uptake was increased in L02 cells with artificial USP18 knockdown (AdshUSP18) (Fig. 4D) . In addition, expression of mRNAs encoded by genes regulating lipid metabolism, serum lipid and lipoprotein levels, and liver function all changed in a deteriorating manner by USP18 knockout (Supporting Fig. S4A-C) . These USP18-HKO HFD mice also suffered hyperglycemia and hyperinsulinemia ( Fig. 4E-G ; Supporting Fig. S4D,E) , which was further supported by constrained glycogen accumulation (Supporting Fig.  S4F-H) . Meanwhile, insulin-signaling cascade activation was inhibited in the livers of USP18-HKO mice fed HFD (Fig. 4H) . Inflammation was increased in USP18-HKO HFD mice compared to controls (Supporting Fig. S4I,J) . Phosphorylation of JNK1 and IKKb, which was inhibited in USP18-HTG HFD mice, was promoted in the livers of USP18-HKO HFD mice. Moreover, IjBa expression was clearly inhibited in USP18-HKO mice (Fig. 4I ).
USP18 EXERTS THERAPEUTIC EFFECTS ON NAFLD IN ob/ob MICE
Based on the observations in USP18-HTG and -HKO HFD mice, we decided to detect whether USP18 has therapeutic effects in ob/ob mice. Eightweek-old ob/ob mice with NAFLD were injected with USP18 recombinant adenovirus (ob/ob-AdUSP18) for 4 weeks to achieve USP18 overexpression in their livers. Controls were treated with AdGFP (Supporting Fig. S5A ). Although their body weights were similar, the livers of ob/ob-AdUSP18 mice gained less weight than the control group ( Fig. 5A; Supporting Fig.  S5B ). Additionally, hepatic steatosis was greatly alleviated by USP18 overexpression in the livers of ob/ob mice (Fig. 5B,C) . The mRNA expression of genes related to fatty acid synthesis and uptake was also constrained in the livers of ob/ob-AdUSP18 mice relative to controls (Fig. 8D) . Fasting blood glucose and insulin levels were reduced in ob/ob-AdUSP18 mice, and the GTT and ITT performed in these mice represented enhanced glucose homeostasis (Fig. 5E,F) ; these results were supported by augmented glycogen storage (by PAS staining) and lowered gluconeogenesis (by real-time PCR analysis of PEPCK and G6PC mRNA expression) (Supporting Fig. S5C,D) . Furthermore, compared to controls, the mRNA transcriptions of proinflammation genes were decreased in the livers of ob/ob-AdUSP18 mice (Fig. 5G) . Activation of insulin-signaling cascades was enhanced while the JNK and NF-jB signaling pathways were suppressed in the liver specimens of ob/ob-AdUSP18 mice compared to controls (Fig. 5H,I ). Collectively, these data suggested that AdUSP18 injection inhibits the progression of NAFLD in ob/ob mice.
TAK1 IS ESSENTIAL FOR USP18 TO REGULATE HEPATIC STEATOSIS, INSULIN SENSITIVITY, AND INFLAMMATION
After observing the therapeutic influences of USP18 in obese animals, we investigated how USP18 helped maintain glucolipid homeostasis and reduce inflammation. Because the JNK and NF-jB signaling pathways were engaged in the regulatory process, we narrowed the target of USP18 to upstream regulators of JNK and IKKb. It is known that TAK1, an upstream kinase of the mitogen-activated protein kinase pathway, regulates the activation of JNK and IKKb. (32, 33) Therefore, we detected TAK1 activation by western blot and found that HFD feeding stimulated the phosphorylation of TAK1 in the livers of USP18-NTG and USP18-Flox mice. However, this enhancement of TAK1 phosphorylation was diminished in USP18-HTG mice (Fig. 6A ) and promoted to a higher level in USP18-HKO mice fed HFD (Fig. 6B) . The same changes were observed in PA-induced primary hepatocytes (Supporting Fig. S6A ). We also found that TAK1 inhibitor (5Z-7-OX) abolished the effects of USP18 knockout in promoting JNK1 and NF-jB activation and restraining insulin-signaling cascades in PA-treated primary hepatocytes (Supporting Fig. S6B,  C) . To further confirm our investigations in steatotic animals, we subjected the HFD-fed USP18-Flox and USP18-HKO mice to intraperitoneal 5Z-7-OX injection for 4 weeks. Littermates injected with dimethyl sulfoxide (DMSO) served as controls (Fig. 6C) . The aggravated effects of USP18 knockout on steatotic phenotypes and inflammation in HFD-fed mice were reversed by blocking TAK1 activation ( Fig. 6D,E; FIG. 6. TAK1 is essential for USP18 to regulate hepatic steatosis, insulin sensitivity, and inflammation. (A,B) TAK1 expression levels in the livers of USP18-HTG (A) and USP18-HKO (B) mice fed NC or HFD (n 5 4/group). The NTG and Flox mice were used as controls. Expression levels were normalized by phosphorylated to total TAK1 (graphs in the right panel). For (A) and (B), all data are presented as the mean 6 SD, *P < 0.05 versus NTG or Flox NC group or # P < 0.05 versus the NTG or Flox HFD group. (C) Expression of USP18 and of phosphorylated and total TAK1 was analyzed in the livers of USP18-Flox or USP18-HKO mice treated with TAK1 inhibitor (5Z-7-OX) or DMSO for 4 weeks after 8-week HFD feeding. For the graphs in the right panel, p-TAK1/TAK1 was used for normalization (n 5 4/group). (D) Histological assay of liver sections from HFD-fed USP18-Flox and USP18-HKO mice with DMSO or 5Z-7-OX treatment (top panel, H&E; bottom panel, oil red O; scale bar, 50 lm; n 5 5/group). (E) Hepatic lipid contents measured in terms of TG, TC, and NEFA (n 5 10/group). (F) Graphs representing fasting blood glucose and insulin levels of USP18-Flox or USP18-HKO mice with DMSO or 5Z-7-OX challenge (n 5 10/group). All data are expressed as the mean 6 SD, *P < 0.05 versus Flox DMSO group or # P < 0.05 versus HKO DMSO group. P > 0.05 was considered statistically nonsignificant. Abbreviation: n.s., no significant difference. Supporting Fig. S6D,E) . Also, the exacerbated glucose metabolic disorders ( Fig. 6F; Supporting Fig. S6F ) and inhibited insulin-signaling pathway (Supporting Fig.  S6G ) caused by USP18 depletion were neutralized by 5Z-7-OX injection. This evidence demonstrates that activation of TAK1 is essential for USP18 to regulate hepatic steatosis, insulin sensitivity, and inflammation.
USP18 INHIBITS TAK1 ACTIVATION THROUGH ITS DUB ACTIVITY
The inhibitory activity of USP18 on TAK1 led us to further explore the molecular mechanisms connecting these two proteins. Using coimmunoprecipitation techniques, we verified that USP18 and TAK1 can associate with each other (Fig. 7A) . Next, truncated Flag-tagged USP18 and TAK1 fragments were used to detect their binding regions. Fragments containing 255-372 amino acids of USP18 can bind to TAK1, and the 1-300 amino acid region of TAK1 interacts with USP18 (Fig. 7B,C) . Because the autophosphorylation of TAK1 requires its ubiquitination, (34) we detected TAK1 ubiquitination in primary hepatocytes and observed a remarkably increased ubiquitination of TAK1 under PA stimulation (Fig. 7D) . Because of this phenomenon and the DUB activity of USP18, we hypothesized that USP18 inhibits TAK1 activation by removing its ubiquitin chains. To test this hypothesis, we analyzed the ubiquitination of TAK1 in liver samples from HFD-fed USP18-HKO and USP18-HTG mice. Compared to the Flox ones, TAK1 ubiquitination was dramatically enhanced in the livers of USP18-HKO mice and almost abrogated by USP18 overexpression (Fig. 7E) , which was also validated in 293T cells by cotransfecting HA-TAK1, Flag-USP18, and Myc-Ub (Fig. 7F) . If the DUB activity of USP18 was deprived by mutating its active site, Cys 64, the reduced TAK1 ubiquitination in USP18-transfected cells was markedly improved in the Flag-USP18 C64S-transfected ones (Fig. 7G) .
THE DUB ACTIVITY OF USP18 IS REQUIRED FOR REGULATING HEPATIC STEATOSIS, INSULIN SENSITIVITY, AND INFLAMMATION
Knowing that the DUB activity of USP18 is vital for regulating TAK1 ubiquitination in cells, we were interested in validating whether this DUB activity plays an essential role in alleviating steatosis and insulin resistance in live animals. After fed HFD for 8 weeks, NAFLD mice were injected with adenovirus containing USP18 or active-site mutant USP18 reconstructs (AdUSP18 or AdUSP18-M); the control littermates were treated with AdGFP. TAK1 activation was enhanced in the livers of AdUSP18-M mice to the same level as the controls, while this activation was inhibited in the AdUSP18 group (Fig. 8A) . In AdUSP18-M HFD mice, we observed that lipid metabolic disorders and liver function were equally aggravated as in the controls, whereas the steatotic changes were greatly diminished by AdUSP18 treatment (Fig.  8B-F) . Additionally, having been deprived of DUB function, AdUSP18-M mice fed HFD developed a higher level of inflammation relative to those with DUB function of USP18 (Fig. 8G) . Although glucose metabolism was significantly improved by AdUSP18 treatment in NAFLD mice, the insulin resistance in AdUSP18-M mice remained unchanged, as in controls (Fig. 8H-L) . Based on these data, the DUB activity of USP18 is essential to alleviate NAFLD.
Discussion
In this study, we observed a sharp reduction in USP18 expression in the liver samples of NASH patients and HFD-induced or genetic deficiencyinduced NAFLD mice. USP18 exerts important functions in regulating innate immunity (16, 17) and tumorigenesis (13, 14) ; however, its effects on the progression of NAFLD have not been investigated yet. Here, we demonstrate that USP18 alleviates hepatic steatosis, insulin resistance, and inflammation. Mechanistically, USP18 interacts with and deubiquitinates TAK1, thus suppressing the downstream JNK and NF-jB signaling pathways.
Among various molecules involved in NAFLD regulation, the TAK1-NF-jB-JNK axis is one of the crucial signaling pathways. As a mitogen-activated protein kinase kinase kinase activated by transforming growth factor-b, TAK1 can phosphorylate IKKb and MKK4/7, leading to activation of NF-jB and JNK signaling, respectively. (33, 35, 36) In this study, we demonstrated that HFD feeding and PA stimulation remarkably promoted TAK1 activation in hepatocytes, which subsequently augmented the downstream JNK and NF-jB signaling pathways. It is known that overactivation of TAK1 by upstream regulators not only exacerbates hepatic steatosis (36) and ischemic/reperfusion injuries in hepatocytes (37) but also mediates cardiac hypertrophy in cardiomyocytes. (35) We here found that the deteriorating effects of USP18 knockout on hepatic steatosis and insulin resistance in HFD mice can be abolished by reducing TAK1 activation with its inhibitor. On the contrary, other studies found that disruption of TAK1 exacerbates lipid metabolic disorders and causes tumorigenesis in hepatocytes. (38) (39) (40) The underlying reasons for these conflicting results are still unknown. It is possible that TAK1 plays essential roles in various physiological and pathological processes and that both total ablation and hyperactivation of TAK1 can induce severe hepatic injuries. Thus, TAK1 activation in hepatocytes needs to be maintained to an appropriate level to achieve glucolipid metabolic homeostasis.
The K63-linked polyubiquitination of TAK1 is required for its autophosphorylation, which results in full activation. (34, 41) Thus, regulation of TAK1 activation can be achieved by adding or removing the ubiquitin chains attached to it. The data collected in our study validated that the 255-372 amino acids of USP18 can associate with the 1-300 amino acids of TAK1 and that the USP domain of USP18 enables its deubiquitinating effect on TAK1. Therefore, the upregulated activation of TAK1 by HFD or PA stimulation was constrained by USP18 through its DUB enzymatic activity in hepatocytes, which is consistent with the results discovered in immune cells. (42, 43) Here, we also provided evidence that treating HFDfed mice with enzymatic active-site mutant USP18 failed to inhibit TAK1 activation. Consequently, these mice exhibited exacerbated phenotypes in hepatic steatosis and insulin resistance compared to the littermates administered AdUSP18, suggesting that the DUB activity of USP18 is indispensable for its protective role against NAFLD.
In the progression of NAFLD, insulin resistance might be developed, switching the hepatocytes from fatty acid oxidation to fatty acid synthesis and resulting in the local storage of fatty acids. (2) The insulin signal-transduction efficacy relies strongly on the phosphorylation of IRS1 at different sites (Ser/Tyr), which is correlated with the subcellular relocalization and proteasome-mediated degradation of IRS1. (27, 44) In addition, activated JNK1 can promote the phosphorylation of IRS1 at Ser307, which subsequently reduces Tyr608-IRS1 phosphorylation, leading to inhibition of the insulin-signaling pathway. (6, 27, 31, 44) Our study confirmed that USP18 inhibits the phosphorylation of JNK1, resulting in repressed Ser307-IRS1 phosphorylation and enhanced Tyr608-IRS1 phosphorylation. This Tyr608-predominant phosphorylation of IRS1 prevented its uncoupling from insulin receptor and led to activation of the downstream Akt. (27) Therefore, the USP18-TAK1-JNK1 axis balances Ser/Tyr-IRS1 phosphorylation to regulate insulin sensitivity in hepatocytes. More importantly, the JNK1 signal is not only the effector of insulin resistance but also a crucial player in the deteriorated hepatic steatosis induced by excessive fat intake. (6, 22, 29, 45) Activation of JNK1 in USP18-depleted hepatocytes resulted in reduced insulin signaling transduction efficacy and steatotic alterations in the liver. Collectively, regulation of USP18 on the TAK1-JNK1 axis is responsible for improving glucolipid metabolic equilibrium in hepatocytes under high-fat stimulation.
It is widely accepted that low-grade inflammation contributes to the development of metabolic dysfunction through abundant crosstalk. Notable pathways that participate in this crosstalk include the JNK and NF-jB signaling pathways. (4, 20, 28, 45) Consumption of HFD strongly activated the NF-jB and JNK signaling FIG. 8 . The DUB activity of USP18 is required for regulating hepatic steatosis, insulin sensitivity, and inflammation. (A) Expression of phosphorylated and total TAK1 in the livers of HFD-fed mice with AdUSP18 or adenovirus encoding active-site mutant USP18 (AdUSP18-M) treatment for 4 weeks and the AdGFP-treated controls after 8-week HFD treatment (n 5 4/group). Phosphorylated TAK1 was normalized to total TAK1 in the right panel. (B) Body weight was measured every 2 weeks (left panel) and liver weight at week 12 of HFD feeding (n 5 10/group). (C,D) TG, TC, and NEFA contained in the liver (C, n 5 10/group), and lipid droplets visualized by H&E (upper panel) or oil red O staining (lower panel) (D; scale bar, 50 lm; n 5 5/group) in the liver sections from AdUSP18, AdUSP18-M, and control mice. (E) Serum lipid and lipoprotein concentrations were also measured (n 5 10/group). (F,G) Liver function and inflammatory response reflected by corresponding parameters in HFD mice with USP18 or active-site mutant USP18 overexpression in the liver (n 5 10/group). (H-L) Fasting blood glucose (H) and insulin (I) levels, homeostasis model assessment of insulin resistance values (J), and the GTT and ITT results (K,L) along with the calculated areas under the curve in AdUSP18 and AdUSP18-M HFD mice compared to their controls (n 5 10/group). All results are presented as the mean 6 SD. *P < 0.05 versus AdGFP HFD group or # P < 0.05 versus AdUSP18 HFD group. P > 0.05 was considered statistically nonsignificant. Abbreviation: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance; MCP-1, monocyte chemoattractant protein 1; n.s., no significant difference; TNF, tumor necrosis factor. pathways, which led to proinflammatory cytokine production. This activation also induced insulin resistance by phosphorylating Ser307-IRS1, (46, 47) linking metabolic dysfunction and inflammation together. When USP18 was overexpressed in hepatocytes, the JNK1 and NF-jB pathways were restrained and subsequently prevented the production of proinflammatory cytokines. Thus, through interrupting the links between these signaling pathways, USP18 breaks the vicious circle comprising hepatic steatosis, insulin resistance, and inflammation.
Importantly, USP18 inhibits or even reverses the progression of NAFLD because the steatotic and inflammatory phenotypes of ob/ob mice were alleviated by AdUSP18 injection. This therapeutic function of USP18 was further confirmed in HFD-induced NAFLD mice. The deubiquitinating activity of USP18 is responsible for its therapeutic function as the enzymatic active-site mutant USP18 failed to inhibit the exacerbated steatosis and inflammation. A previous study reported that USP18 could remove ISG15, a ubiquitin-like protein, from various substrates to modulate hepatitis C virus infection, (48) implying multiple functions of USP18. Therefore, the regulatory mechanisms of USP18 in different diseases are stressdependent.
In conclusion, we observed down-regulated expression of USP18 in the liver specimens obtained from NASH patients and HFD-induced or genetically obese mice. Our data show that USP18 inhibits hepatic steatosis, promotes insulin signaling activation, and attenuates chronic inflammation. The underlying mechanism is also elucidated: USP18 deubiquitinates TAK1 to inhibit its activation through DUB activity, which constrains the downstream JNK and NF-jB signaling pathways. Importantly, USP18 could provide new insights into the pathogenesis of NAFLD and open a new direction for the development of therapies for this disease.
